{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:26:03Z","timestamp":1793834763486,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Preeclampsia is characterized by endothelial dysfunction and angiogenic imbalance driven, in part, by excess soluble fms-like tyrosine kinase-1 (sFLT-1). Building on previous findings demonstrating vascular modulatory effects of cardiac and quercetin glycosides from Dacryodes edulis seeds during L-NAME-induced vascular perturbation, we investigated whether pear seed glycosides (PSG) modulate sFLT-1-mediated endothelial injury in preeclampsia. Endothelial, preclinical, biophysical, pharmacodynamic, and exploratory clinical approaches were integrated to evaluate PSG activity. TGF\u03b2-stimulated HUVECs, an L-NAME-induced rat model of preeclampsia, orthogonal binding assays (SPR\/BLI and MST), ligand competition assays, and a multicenter double-blind phase 1-2a exploratory clinical trial were employed. PSG reduced endothelial migration and suppressed \u03b1SMA, TNF\u03b1, and fibronectin expression in stimulated HUVECs. In preeclamptic rats, PSG attenuated systolic and diastolic blood pressure elevation, reduced inflammatory and cardiovascular injury markers, restored VEGF and placental growth factor (PlGF), and reduced circulating sFLT-1 and the sFLT-1\/PlGF ratio. Bioactivity-guided fractionation identified glycosides as the principal active fraction and improved mean birth weight from 2.7\u2009g in untreated preeclamptic dams to 3.5\u2009g, approaching normotensive controls (3.7\u2009g). Orthogonal SPR\/BLI and MST assays demonstrated concentration-dependent PSG-sFLT-1 interactions, while competitive ELISA and BLI assays showed inhibition of sFLT-1-mediated sequestration of VEGF and PlGF. PSG additionally restored VEGFR2\/KDR, AKT, and ERK signaling in sFLT-1-exposed endothelial cells. In the exploratory clinical trial, 83 participants were randomized following screening of 125 women, with approximately 80% completing follow-up. PSG administration alongside standard care did not reveal major treatment-emergent safety concerns. These findings support further investigation of PSG as a candidate adjunctive strategy targeting angiogenic dysfunction in preeclampsia.<\/jats:p>","DOI":"10.1038\/s41440-026-02770-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:57:46Z","timestamp":1788271066000},"page":"3177-3193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycoside fraction from pear seed functionally antagonizes sFLT-1 and restores angiogenic signaling in preeclampsia"],"prefix":"10.1038","volume":"49","author":[{"given":"Peter U.","family":"Amadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justice O.","family":"Osuoha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieme J.","family":"Ogbolosingha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind S.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suha J.","family":"Jarad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince C.","family":"Odika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esienanwan E.","family":"Efiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayem A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel N.","family":"Agomuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queendarlyn","family":"Agbagwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiamaka W.","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy A.","family":"Amadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestine N.","family":"Ekweogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-mei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"2770_CR1","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s12015-024-10739-x","volume":"20","author":"J Cui","year":"2024","unstructured":"Cui J, Yang Z, Ma R, He W, Tao H, Li Y, et al. Placenta-targeted treatment strategies for preeclampsia and fetal growth restriction: an opportunity and major challenge. Stem Cell Rev Rep. 2024;20:1501\u201311.","journal-title":"Stem Cell Rev Rep"},{"key":"2770_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.placenta.2020.08.022","volume":"102","author":"N de Alwis","year":"2020","unstructured":"de Alwis N, Binder NK, Beard S, Kaitu\u2019u-Lino TJ, Tong S, Brownfoot F, et al. Novel approaches to combat preeclampsia: from new drugs to innovative delivery. Placenta. 2020;102:10\u20136.","journal-title":"Placenta"},{"key":"2770_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1152\/physrev.00021.2018","volume":"99","author":"S Piera-Velazquez","year":"2019","unstructured":"Piera-Velazquez S, Jimenez SA. Endothelial to mesenchymal transition: Role in physiology and in the pathogenesis of human diseases. Physiol Rev. 2019;99:1281\u2013324.","journal-title":"Physiol Rev"},{"key":"2770_CR4","first-page":"17","volume":"47","author":"C Tardif","year":"2018","unstructured":"Tardif C, Dumontet E, Caillon H, Misbert E, Dochez V, Masson D, et al. Angiogenic factors sFlt-1 and PlGF in preeclampsia: Prediction of risk and prognosis in a high-risk obstetric population. J Gynecol Obstet. Hum Reprod. 2018;47:17\u201321.","journal-title":"Hum Reprod"},{"key":"2770_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13224-011-0092-x","volume":"61","author":"U Krishna","year":"2011","unstructured":"Krishna U, Bhalerao S. Placental insufficiency and fetal growth restriction. J Obstet Gynaecol India. 2011;61:505.","journal-title":"J Obstet Gynaecol India"},{"key":"2770_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.120.15338","volume":"76","author":"E Lecarpentier","year":"2020","unstructured":"Lecarpentier E, Zsengell\u00e9r ZK, Salahuddin S, Covarrubias AE, Lo A, Haddad B, et al. Total versus free placental growth factor levels in the pathogenesis of preeclampsia. Hypertension. 2020;76:875\u201383.","journal-title":"Hypertension"},{"key":"2770_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","volume":"111","author":"SE Maynard","year":"2003","unstructured":"Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649\u201358.","journal-title":"J Clin Invest"},{"key":"2770_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/cts.12742","volume":"13","author":"V Kojovic D","year":"2020","unstructured":"Kojovic D V, Workewych N, Piquette-Miller M. Role of elevated SFLT-1 on the regulation of placental transporters in women with pre-eclampsia. Clin Transl Sci. 2020;13:580.","journal-title":"Clin Transl Sci"},{"key":"2770_CR9","first-page":"2438","volume":"27","author":"I Akbarzadeh","year":"2026","unstructured":"Akbarzadeh I, Heidari F, Nwoke S, Liu C, Jankovic-Karasoulos T, McClements L. Angiogenic imbalance models of preeclampsia: from mechanisms to clinics. Hypertension. 2026;27:2438.","journal-title":"Hypertension"},{"key":"2770_CR10","doi-asserted-by":"publisher","first-page":"102963","DOI":"10.1016\/j.jogc.2025.102963","volume":"47","author":"L Ghesqui\u00e8re","year":"2025","unstructured":"Ghesqui\u00e8re L, Bujold E, Djedid Y, Masmoudi A, Magherbi H, Ayari F, et al. Prospective study evaluating the association between sFlt-1\/PlGF ratio and adverse outcomes in preterm preeclampsia. J Obstet Gynaecol Can. 2025;47:102963.","journal-title":"J Obstet Gynaecol Can"},{"key":"2770_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1161\/HYPERTENSIONAHA.125.24736","volume":"82","author":"A Jungelson","year":"2025","unstructured":"Jungelson A, Ridoux A, Barthe M, Redel D, Abbas H, Haddad B, et al. Total and free placental growth factor levels during preeclampsia and fetal growth restriction. Hypertension. 2025;82:883\u201393.","journal-title":"Hypertension"},{"key":"2770_CR12","doi-asserted-by":"publisher","first-page":"2648178","DOI":"10.1080\/14767058.2026.2648178","volume":"39","author":"MN Irby","year":"2026","unstructured":"Irby MN, Hsu CD, Winget V, Srinivasan SA, Goyal R. Present status of sFLT1 and PlGF as diagnostic and therapeutic targets for preeclampsia. J Matern Fetal Neonatal Med. 2026;39:2648178.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2770_CR13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nbt.4297","volume":"36","author":"AA Turanov","year":"2018","unstructured":"Turanov AA, Lo A, Hassler MR, Makris A, Ashar-Patel A, Alterman JF, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018;36:1164\u201373.","journal-title":"Nat Biotechnol"},{"key":"2770_CR14","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/s41591-026-04333-6","volume":"32","author":"R Thadhani","year":"2026","unstructured":"Thadhani R, Hiemstra TF, Vatish M, Stepan H, Cerdeira AS, Brockelsby J, et al. Targeted removal of soluble Fms-like tyrosine kinase 1 in very preterm preeclampsia: a pilot trial. Nat Med. 2026;32:2173\u201381.","journal-title":"Nat Med"},{"key":"2770_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/jbcpp-2019-0116","volume":"31","author":"PU Amadi","year":"2020","unstructured":"Amadi PU, Agomuo EN, Adumekwe CW. Modulatory properties of cardiac and quercetin glycosides from Dacryodes edulis seeds during L-NAME-induced vascular perturbation. J Basic Clin Physiol Pharm. 2020;31:1\u20136.","journal-title":"J Basic Clin Physiol Pharm"},{"key":"2770_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.preghy.2022.06.007","volume":"29","author":"A Mazurakova","year":"2022","unstructured":"Mazurakova A, Koklesova L, Samec M, Kudela E, Sivakova J, Pribulova T, et al. Flavonoids exert potential in the management of hypertensive disorders in pregnancy. Pregnancy Hypertens. 2022;29:72\u201385.","journal-title":"Pregnancy Hypertens"},{"key":"2770_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1038\/s41440-025-02144-9","volume":"48","author":"T Ushida","year":"2025","unstructured":"Ushida T, Tano S, Matsuo S, Fuma K, Imai K, Kajiyama H, et al. Dietary supplements and prevention of preeclampsia. Hypertens Res. 2025;48:1444\u201357.","journal-title":"Hypertens Res"},{"key":"2770_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/ph14030269","volume":"14","author":"M O\u017carowski","year":"2021","unstructured":"O\u017carowski M, Karpi\u0144ski TM, Szulc M, Wielgus K, Kujawski R, Wolski H, et al. Plant phenolics and extracts in animal models of preeclampsia and clinical trials\u2014review of perspectives for novel therapies. Pharmaceuticals. 2021;14:269.","journal-title":"Pharmaceuticals"},{"key":"2770_CR19","doi-asserted-by":"publisher","first-page":"A3.B.1","DOI":"10.1002\/0471142735.ima03bs111","volume":"111","author":"W Strober","year":"2015","unstructured":"Strober W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 2015;111:A3.B.1.","journal-title":"Curr Protoc Immunol"},{"key":"2770_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/medsci7020013","volume":"7","author":"EN Agomuo","year":"2019","unstructured":"Agomuo EN, Amadi PU, Adumekwe C. Gestational Geophagia Affects Nephrocardiac Integrity, ATP-Driven Proton Pumps, the Renin-Angiotensin\u2013Aldosterone System, and F2-Isoprostane Status. Med Sci. 2019;7:13.","journal-title":"Med Sci"},{"key":"2770_CR21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejogrb.2014.08.021","volume":"182","author":"S Baijnath","year":"2014","unstructured":"Baijnath S, Soobryan N, Mackraj I, Gathiram P, Moodley J. The optimization of a chronic nitric oxide synthase (NOS) inhibition model of pre-eclampsia by evaluating physiological changes. Eur J Obstet Gynecol Reprod Biol. 2014;182:71\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2770_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351\u20138.","journal-title":"Anal Biochem"},{"key":"2770_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1172\/JCI111550","volume":"74","author":"SL Marklund","year":"1984","unstructured":"Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Investig. 1984;74:1398\u2013403.","journal-title":"J Clin Investig"},{"key":"2770_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0076-6879(84)05016-3","volume":"105","author":"H Aebi","year":"1984","unstructured":"Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121\u20136.","journal-title":"Methods Enzymol"},{"key":"2770_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.preghy.2023.10.005","volume":"34","author":"AD Bhat","year":"2023","unstructured":"Bhat AD, Keasler PM, Kolluru L, Dombrowski MM, Palanisamy A, Singh PM. Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration. Pregnancy Hypertens. 2023;34:74\u201382.","journal-title":"Pregnancy Hypertens"},{"key":"2770_CR26","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.12688\/f1000research.125944.2","volume":"11","author":"SD Novri","year":"2023","unstructured":"Novri SD, Hamidy DA, Savira Y, Effectiveness M. of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial. F1000Res. 2023;11:1287.","journal-title":"F1000Res"},{"key":"2770_CR27","doi-asserted-by":"publisher","first-page":"100352","DOI":"10.1016\/j.xagr.2024.100352","volume":"4","author":"E Kupka","year":"2024","unstructured":"Kupka E, Roberts JM, Mahdy ZA, Escudero C, Bergman L, De Oliveira L. Aspirin for preeclampsia prevention in low- and middle-income countries: mind the gaps. AJOG Glob Rep. 2024;4:100352.","journal-title":"AJOG Glob Rep"},{"key":"2770_CR28","doi-asserted-by":"publisher","first-page":"e22801","DOI":"10.1097\/MD.0000000000022801","volume":"99","author":"G He","year":"2020","unstructured":"He G, Chen Y, Chen M, He G, Liu X. Efficacy and safety of low dose aspirin and magnesium sulfate in the treatment of pregnancy induced hypertension: A protocol for systematic review and meta-analysis. Medicine. 2020;99:e22801.","journal-title":"Medicine"},{"key":"2770_CR29","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","volume":"124","author":"S Rana","year":"2019","unstructured":"Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res. 2019;124:1094\u2013112.","journal-title":"Circ Res"},{"key":"2770_CR30","first-page":"622","volume":"39","author":"JP Guida","year":"2017","unstructured":"Guida JP, de S, Surita FG, Parpinelli MA, Costa ML. Preterm preeclampsia and timing of delivery: a systematic literature review. RBGO Gynecol Obstet. 2017;39:622.","journal-title":"RBGO Gynecol Obstet"},{"key":"2770_CR31","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jacc.2020.08.014","volume":"76","author":"CW Ives","year":"2020","unstructured":"Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia\u2014Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;76:1690\u2013702.","journal-title":"J Am Coll Cardiol"},{"key":"2770_CR32","doi-asserted-by":"publisher","first-page":"101861","DOI":"10.1016\/j.redox.2021.101861","volume":"40","author":"P Guerby","year":"2021","unstructured":"Guerby P, Tasta O, Swiader A, Pont F, Bujold E, Parant O, et al. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. Redox Biol. 2021;40:101861.","journal-title":"Redox Biol"},{"key":"2770_CR33","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1161\/CIRCULATIONAHA.109.853127","volume":"123","author":"CE Powe","year":"2011","unstructured":"Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of anti-angiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856\u201369.","journal-title":"Circulation"},{"key":"2770_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13293-018-0195-5","volume":"9","author":"AC Eddy","year":"2018","unstructured":"Eddy AC, Bidwell GL, George EM. Pro-angiogenic therapeutics for preeclampsia. Biol Sex Differ. 2018;9:36.","journal-title":"Biol Sex Differ"},{"key":"2770_CR35","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/biom10060953","volume":"10","author":"MK Jena","year":"2020","unstructured":"Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of preeclampsia and therapeutic approaches targeting the placenta. Biomolecules. 2020;10:953.","journal-title":"Biomolecules"},{"key":"2770_CR36","doi-asserted-by":"publisher","first-page":"250009","DOI":"10.1530\/VB-25-0009","volume":"7","author":"S Palo","year":"2025","unstructured":"Palo S, Mangla M, Motwani R, Palo S, Mangla M, Motwani R. sFlt-1\/PlGF and beyond: angiolymphatic-associated signatures and emerging biomarkers in placental pathology. Vasc Biol. 2025;7:250009.","journal-title":"Vasc Biol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02770-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:04:25Z","timestamp":1793833465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02770-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2770"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02770-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}